Fused heterocyclic derivatives as s1p modulators

The disclosure relates to a fused heterocyclic derivative of the formula (I), wherein the variables R1-R4, z, A, Q, X and Y are as defined in the specification. 4-{ 2-[4-(2-Fluoro-benzyloxy)-phenyl]-6,7-dihydro-4H-furo[3,2-c]pyridine-5-yl} -butyric acid is a typical example of said fused heterocycli...

Full description

Saved in:
Bibliographic Details
Main Authors VAN DONGEN MARIA J.P, SMID PIETER, SLIEDREGT LEONARDUS A.J.M, DEN HARTOG JACOBUS A.J, COOLEN HEIN K.A.C, IWEMA BAKKER WOUTER I, ADRIAN D. HOBSON
Format Patent
LanguageEnglish
Published 29.08.2014
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The disclosure relates to a fused heterocyclic derivative of the formula (I), wherein the variables R1-R4, z, A, Q, X and Y are as defined in the specification. 4-{ 2-[4-(2-Fluoro-benzyloxy)-phenyl]-6,7-dihydro-4H-furo[3,2-c]pyridine-5-yl} -butyric acid is a typical example of said fused heterocyclic derivative. These compounds of formula (I) are modulators of the S1P receptor (Sphingosine-1-phosphate receptor). More specifically, they are agonists of S1P5. The compounds have therapeutic use in treatment of neurodegenerative disorder, in particular selected from a cognitive disorder, Alzheimer's disease, (vascular) dementia, Nieman's Pick disease, and cognitive deficits in schizophrenia, obsessive-compulsive behaviour, major depression, autism, multiple sclerosis and pain, and specifically a cognitive disorder, such as age-related cognitive decline.
Bibliography:Application Number: NZ20110605491